(Q38543439)

English

The efficacy of Botulinum Toxin A for limb spasticity on improving activity restriction and quality of life: a systematic review and meta-analysis using the GRADE approach

scientific article published on 06 July 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 September 2017

0 references

1 reference

Europe PubMed Central

The efficacy of Botulinum Toxin A for limb spasticity on improving activity restriction and quality of life: a systematic review and meta-analysis using the GRADE approach (English)

1 reference

Europe PubMed Central

4 September 2017

quality of life

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Jennifer A Baker

1

1 reference

Europe PubMed Central

4 September 2017

Gavin Pereira

2

1 reference

Europe PubMed Central

4 September 2017

publication date

6 July 2015

1 reference

Europe PubMed Central

4 September 2017

Clinical Rehabilitation

1 reference

Europe PubMed Central

4 September 2017

30

1 reference

Europe PubMed Central

4 September 2017

6

1 reference

Europe PubMed Central

4 September 2017

549-558

1 reference

Europe PubMed Central

4 September 2017

Grading quality of evidence and strength of recommendations

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement.

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

Botulinum treatment of spasticity: why is it so difficult to show a functional benefit?

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: a meta-analysis

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

Results from the Upper Limb International Spasticity Study-II (ULISII):a large, international, prospective cohort study investigating practice and goal attainment following treatment with botulinum toxin A in real-life clinical management.

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

The efficacy of Botulinum Toxin A for spasticity and pain in adults: a systematic review and meta-analysis using the Grades of Recommendation, Assessment, Development and Evaluation approach

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

A new system for grading recommendations in evidence based guidelines

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

GRADE guidelines: 2. Framing the question and deciding on important outcomes.

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

GRADE guidelines: 3. Rating the quality of evidence

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias)

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

GRADE guidelines: 5. Rating the quality of evidence--publication bias

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

GRADE guidelines 6. Rating the quality of evidence—imprecision

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

GRADE guidelines: 7. Rating the quality of evidence--inconsistency

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

GRADE guidelines: 8. Rating the quality of evidence--indirectness

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

GRADE guidelines: 9. Rating up the quality of evidence

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

Does low-dose botulinum toxin help the recovery of arm function when given early after stroke? A phase II randomized controlled pilot study to estimate effect size

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

Functional goal achievement in post-stroke spasticity patients: the BOTOX® Economic Spasticity Trial (BEST).

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes.

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

A Preliminary Assessment of the Benefits of the Addition of Botulinum Toxin A to a Conventional Therapy Program on the Function of People With Longstanding Stroke

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

A prospective, multicentre, randomized, double-blind, placebo-controlled trial of onabotulinumtoxinA to treat plantarflexor/invertor overactivity after stroke

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

Evaluating the role of botulinum toxin in the management of focal hypertonia in adults

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

Botulinum toxin type A for upper limb spasticity following stroke: an open-label study with individualised, flexible injection regimens.

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

Combined botulinum toxin type A with modified constraint-induced movement therapy for chronic stroke patients with upper extremity spasticity: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

Botulinum toxin to treat upper-limb spasticity in hemiparetic patients: analysis of function and kinematics of reaching movements.

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

Effect of simultaneous botulinum toxin injections into several muscles on impairment, activity, participation, and quality of life among stroke patients presenting with a stiff knee gait.

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

Botulinum toxin A (BoNT-A) for spasticity in adults. What is the evidence?

1 reference

https://api.crossref.org/works/10.1177%2F0269215515593609

21 January 2018

Identifiers

10.1177/0269215515593609

1 reference

Europe PubMed Central

4 September 2017

1 reference

Europe PubMed Central

4 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38543439&oldid=1766524291"